CA2771789C - Polytherapie pour traiter des maladies proliferatives - Google Patents

Polytherapie pour traiter des maladies proliferatives Download PDF

Info

Publication number
CA2771789C
CA2771789C CA2771789A CA2771789A CA2771789C CA 2771789 C CA2771789 C CA 2771789C CA 2771789 A CA2771789 A CA 2771789A CA 2771789 A CA2771789 A CA 2771789A CA 2771789 C CA2771789 C CA 2771789C
Authority
CA
Canada
Prior art keywords
optionally substituted
meo
alkyl
aryl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2771789A
Other languages
English (en)
Other versions
CA2771789A1 (fr
Inventor
Gabriel Kremmidiotis
David Bibby
Annabell Leske
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionomics Ltd
Original Assignee
Bionomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009904098A external-priority patent/AU2009904098A0/en
Application filed by Bionomics Ltd filed Critical Bionomics Ltd
Publication of CA2771789A1 publication Critical patent/CA2771789A1/fr
Application granted granted Critical
Publication of CA2771789C publication Critical patent/CA2771789C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition pharmaceutique d'un inhibiteur de polymérisation de la tubuline et d'un inhibiteur mTOR ainsi qu'un procédé de traitement des maladies prolifératives avec une combinaison d'un inhibiteur de polymérisation de la tubuline et d'un inhibiteur mTOR.
CA2771789A 2009-08-27 2010-08-25 Polytherapie pour traiter des maladies proliferatives Expired - Fee Related CA2771789C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2009904098A AU2009904098A0 (en) 2009-08-27 Combination Therapy
AU2009904098 2009-08-27
PCT/AU2010/001097 WO2011022772A1 (fr) 2009-08-27 2010-08-25 Polythérapie pour traiter des maladies prolifératives

Publications (2)

Publication Number Publication Date
CA2771789A1 CA2771789A1 (fr) 2011-03-03
CA2771789C true CA2771789C (fr) 2018-01-02

Family

ID=43627078

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2771789A Expired - Fee Related CA2771789C (fr) 2009-08-27 2010-08-25 Polytherapie pour traiter des maladies proliferatives

Country Status (10)

Country Link
US (1) US9006284B2 (fr)
EP (1) EP2470177B1 (fr)
JP (2) JP6141016B2 (fr)
CN (2) CN106822083A (fr)
AU (1) AU2010286334B2 (fr)
CA (1) CA2771789C (fr)
ES (1) ES2545340T3 (fr)
IL (1) IL218283A (fr)
NZ (1) NZ598489A (fr)
WO (1) WO2011022772A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011022772A1 (fr) 2009-08-27 2011-03-03 Bionomics Limited Polythérapie pour traiter des maladies prolifératives
AU2009240878B2 (en) * 2009-11-27 2016-05-26 Bionomics Limited Combination Therapy for Treating Proliferative Diseases
US8674119B2 (en) 2010-07-16 2014-03-18 Bionomics Limited Chemical processes for the manufacture of substituted benzofurans
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
CA2855994A1 (fr) * 2011-12-09 2013-06-13 Demerx, Inc. Esters phosphoriques de noribogaine
CA2896133A1 (fr) 2012-12-20 2014-06-26 Demerx, Inc. Noribogaine substituee
CA2940983A1 (fr) * 2014-03-03 2015-09-11 Eisai R&D Management Co., Ltd. Utilisation d'eribuline et d'inhibiteurs de mtor en tant que polytherapie pour le traitement du cancer
NZ724796A (en) * 2014-04-04 2019-04-26 Bionomics Ltd Method for treating chronic lymphocytic leukemia
US10159659B2 (en) 2014-07-02 2018-12-25 Bionomics Limited Predicting response to cancer therapy
TWI594982B (zh) * 2014-08-13 2017-08-11 杏國新藥股份有限公司 低細胞毒性血管阻斷劑
AU2016228116A1 (en) * 2015-03-05 2017-09-14 Bionomics Limited Combination treatment protocol
US20200354336A9 (en) * 2017-08-11 2020-11-12 Unity Biotechnology, Inc. Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells
US11478445B2 (en) * 2017-10-25 2022-10-25 Bionomics Ltd. Method for treating acute myeloid leukemia
US20220143050A1 (en) * 2019-02-22 2022-05-12 Kazumoto Murata mTOR Inhibitor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340062A (en) 1992-08-13 1994-08-23 Harmon Industries, Inc. Train control system integrating dynamic and fixed data
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US5886025A (en) 1997-03-06 1999-03-23 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
US6162930A (en) 1998-03-06 2000-12-19 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
US6309374B1 (en) 1998-08-03 2001-10-30 Insite Vision Incorporated Injection apparatus and method of using same
EP1154691A4 (fr) 1999-01-05 2004-07-07 Massachusetts Eye & Ear Infirm Administration ciblee de medicament a liberation regulee vers la retine et la choroide a travers la sclerotique
EP1214298B1 (fr) 1999-09-17 2012-05-30 Baylor University Agents de polymerisation antimitotiques et antitubulines contenant de l'indole et apparentes a la combretastatine
US6849656B1 (en) 1999-09-17 2005-02-01 Baylor University Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
CA2407967C (fr) 2000-03-10 2010-10-05 Baylor University Ligands de liaison de tubuline et constructions correspondantes de promedicaments
AUPR283801A0 (en) 2001-02-01 2001-03-01 Australian National University, The Chemical compounds and methods
JP2004536847A (ja) 2001-07-13 2004-12-09 オキシジーン， インコーポレイテッド 眼の疾患の処置のためのチューブリン結合薬剤を投与するための組成物および方法
WO2003070241A1 (fr) 2002-02-15 2003-08-28 Rigel Pharmaceuticals, Inc. Inhibiteurs de la polymerisation de tubuline
US20050074497A1 (en) 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
KR20060085246A (ko) 2003-09-18 2006-07-26 마커사이트, 인코포레이티드 경공막 전달
US7456214B2 (en) 2004-05-03 2008-11-25 Baylor University Chromene-containing compounds with anti-tubulin and vascular targeting activity
WO2006043965A1 (fr) 2004-10-14 2006-04-27 Allergan, Inc. Compositions ophtalmiques therapeutiques contenant des excipients sans danger pour la retine et leurs methodes
AU2006212726C1 (en) * 2005-02-14 2013-05-16 Bionomics Limited Novel tubulin polymerisation inhibitors
ES2551086T3 (es) 2005-06-14 2015-11-16 Baylor University Análogos de combretastatina con actividad de unión a tubulina
JP5315060B2 (ja) * 2006-02-03 2013-10-16 バイオノミックス リミテッド 置換ベンゾフラン、ベンゾチオフェン、ベンゾセレノフェンおよびインドールおよびそれらのチューブリン重合阻害剤としての使用
WO2008027013A2 (fr) * 2006-08-29 2008-03-06 National Cancer Centre Composition et procédé
US8466163B2 (en) 2006-12-11 2013-06-18 Bionomics Limited Furo[2,3-d]pyrimidines and related compounds and methods for treating disease states by inhibiting tubulin polymerization
US20090274698A1 (en) * 2007-07-06 2009-11-05 Shripad Bhagwat Combination anti-cancer therapy
EP2470519B1 (fr) 2009-08-27 2014-12-17 Bionomics Limited Traitement de la dégénérescence maculaire
WO2011022772A1 (fr) 2009-08-27 2011-03-03 Bionomics Limited Polythérapie pour traiter des maladies prolifératives

Also Published As

Publication number Publication date
ES2545340T3 (es) 2015-09-10
AU2010286334B2 (en) 2016-02-04
US9006284B2 (en) 2015-04-14
EP2470177A4 (fr) 2013-07-17
JP6141016B2 (ja) 2017-06-07
JP2013502439A (ja) 2013-01-24
WO2011022772A1 (fr) 2011-03-03
US20120149665A1 (en) 2012-06-14
EP2470177B1 (fr) 2015-07-15
JP2016028040A (ja) 2016-02-25
IL218283A (en) 2017-03-30
AU2010286334A1 (en) 2012-02-23
IL218283A0 (en) 2012-04-30
HK1172257A1 (en) 2013-04-19
EP2470177A1 (fr) 2012-07-04
CN106822083A (zh) 2017-06-13
CN102596197A (zh) 2012-07-18
CA2771789A1 (fr) 2011-03-03
NZ598489A (en) 2014-03-28

Similar Documents

Publication Publication Date Title
CA2771789C (fr) Polytherapie pour traiter des maladies proliferatives
AU2013204313B2 (en) Combination Therapy
PT1984333E (pt) Benzofuranos, benzotiofenos, benzoselenofenos e indóis substituídos e sua utilização como inibidores da polimerização da tubulina
JP2008530030A (ja) 新規なチューブリン重合阻害剤
US20180289739A1 (en) Combination Therapy for Treating Proliferative Diseases
AU2014389437B2 (en) Method for treating chronic lymphocytic leukemia
CN116322674B (zh) 用于根除癌症干细胞并诱导damp介导的抗肿瘤免疫反应的一组新型copi/arf1-脂解途径抑制剂和化合物
US9399644B2 (en) [1,3] dioxolo [4,5-G] quinoline-6(5H)thione derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer
AU2015264805B2 (en) Combination Therapy
HK1172257B (en) Combination therapy for treating proliferative diseases
CA2686587C (fr) Traitement d'association destine a des maladies proliferatives
AU2009240878B2 (en) Combination Therapy for Treating Proliferative Diseases
US20170119727A1 (en) A therapeutic protocol for treating ovarian cancer
HK1207286B (en) Combinations of a vascular disrupting agent and a hypoxia-targeting agent for use in the treatment of cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150806

MKLA Lapsed

Effective date: 20220301

MKLA Lapsed

Effective date: 20200831